FIELD: medicine, pharmacology. SUBSTANCE: invention proposes hexapeptide of the structural formula: lysyl-histidyl-glycyl-lysyl-histidyl-glycine as a drug. Drug has glycine as a stabilizing agent additionally. Drug shows high effectiveness of action with respect to stimulation of humoral immunity, immune response potency and molecules of intermolecular interaction in therapy of immunodeficiency states. EFFECT: enhanced effectiveness of agent. 3 cl, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATMENT OF PATIENTS WITH IMMUNODEFICINCY STATE | 1999 |
|
RU2157235C1 |
| PREPARATION FOR OVERCOMING MULTIDRUG RESISTANCE | 2008 |
|
RU2434879C2 |
| PREPARATION FOR TREATING INFLAMMATORY DISEASES | 2000 |
|
RU2170101C1 |
| AGENT STIMULATING ANTIGEN-NONDEPENDING DIFFERENTIATION OF LYMPHOCYTE B | 2000 |
|
RU2166956C1 |
| AGENT FOR COPING WITH STEROID RESISTANCE | 2009 |
|
RU2404792C1 |
| METHOD FOR EVALUATING FUNCTIONAL STATE OF IMMUNITY SYSTEM IN PATIENTS CEREBRAL INJURIES | 2001 |
|
RU2184969C1 |
| AGENT ELICITING IMMUNOSTIMULATING ACTIVITY | 2000 |
|
RU2177803C1 |
| METHOD OF PREVENTION AND CORRECTION OF TOXIC IMMUNE ALTERATIONS | 2007 |
|
RU2364396C2 |
| DIAGNOSTIC TECHNIQUE FOR EARLY CONGENITAL LATENT SYPHILIS | 2010 |
|
RU2421730C1 |
| MODEL OF HLA-INCOMPATIBLE HUMANIZED NSG MOUSE WITH XENOGRAFT OBTAINED FROM A PATIENT | 2016 |
|
RU2757421C2 |
